April 2, 2018 / 12:29 PM / 20 days ago

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

April 2 (Reuters) - Idera Pharmaceuticals Inc:

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS’ PROPOSED MERGER WITH IDERA PHARMACEUTICALS

* ‍RA CAPITAL MANAGEMENT SAYS HAS BENEFICIAL OWNERSHIP OF ABOUT 7.1 PERCENT OF BIOCRYST PHARMACEUTICALS’ COMMON STOCK​

* RA CAPITAL SAYS HAS “SERIOUS CONCERNS” ABOUT BIOCRYST PHARMACEUTICALS’ PROPOSED DEAL WITH IDERA AND ITS “DILUTIVE IMPACT” ON BIOCRYST SHAREHOLDERS ‍​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below